| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 646 | 2020 |
| Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases A Lipton, GG Steger, J Figueroa, C Alvarado, P Solal-Celigny, JJ Body, ... Journal of Clinical Oncology 25 (28), 4431-4437, 2007 | 459 | 2007 |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 456 | 2015 |
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) C Pinto, F Di Fabio, S Siena, S Cascinu, FLR Llimpe, C Ceccarelli, V Mutri, ... Annals of Oncology 18 (3), 510-517, 2007 | 411 | 2007 |
| Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab M Scartozzi, E Galizia, S Chiorrini, R Giampieri, R Berardi, C Pierantoni, ... Annals of oncology 20 (2), 227-230, 2009 | 386 | 2009 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 332 | 2019 |
| Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with … M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu Journal of clinical oncology 22 (23), 4772-4778, 2004 | 329 | 2004 |
| Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with … M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu Journal of clinical oncology 22 (23), 4772-4778, 2004 | 329 | 2004 |
| Metabolic phenotype of bladder cancer F Massari, C Ciccarese, M Santoni, R Iacovelli, R Mazzucchelli, F Piva, ... Cancer treatment reviews 45, 46-57, 2016 | 226 | 2016 |
| Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy A Lipton, GG Steger, J Figueroa, C Alvarado, P Solal-Celigny, JJ Body, ... Clinical Cancer Research 14 (20), 6690-6696, 2008 | 182 | 2008 |
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial S Cascinu, R Berardi, R Labianca, S Siena, A Falcone, E Aitini, S Barni, ... The lancet oncology 9 (1), 39-44, 2008 | 175 | 2008 |
| Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients M Mandalà, M Reni, S Cascinu, S Barni, I Floriani, S Cereda, R Berardi, ... Annals of oncology 18 (10), 1660-1665, 2007 | 168 | 2007 |
| Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy M Scartozzi, I Bearzi, C Pierantoni, A Mandolesi, F Loupakis, A Zaniboni, ... Journal of clinical oncology 25 (25), 3930-3935, 2007 | 155 | 2007 |
| Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study D Santini, M Tampellini, B Vincenzi, T Ibrahim, C Ortega, V Virzi, ... Annals of oncology 23 (8), 2072-2077, 2012 | 154 | 2012 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 153 | 2019 |
| Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib C Lolli, U Basso, L Derosa, E Scarpi, T Sava, M Santoni, SJ Crabb, ... Oncotarget 7 (34), 54564, 2016 | 153 | 2016 |
| Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges F Tartari, M Santoni, L Burattini, P Mazzanti, A Onofri, R Berardi Cancer treatment reviews 48, 20-24, 2016 | 147 | 2016 |
| Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma M Santoni, F Massari, C Amantini, M Nabissi, F Maines, L Burattini, ... Cancer immunology, immunotherapy 62, 1757-1768, 2013 | 144 | 2013 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 136 | 2019 |
| ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016 C Dittrich, M Kosty, S Jezdic, D Pyle, R Berardi, J Bergh, N El-Saghir, ... ESMO open 1 (5), e000097, 2016 | 133 | 2016 |
